Education
About Us
Working with TipRanks
Follow Us
Fusion Antibodies Plc (GB:FAB)
LSE:FAB
RESEARCH TOOLSreports
FAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range2.80p - 12.00p
Previous CloseN/A
Volume21.95K
Average Volume (3M)467.86K
Market Cap
£8.13M
Enterprise Value7.04M
Total Cash (Recent Filing)£439.00K
Total Debt (Recent Filing)£32.00K
Price to Earnings (P/E)―
Beta-0.51
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding113,656,250
10 Day Avg. Volume667,636
30 Day Avg. Volume467,860
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)5.90
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Fusion Antibodies Plc News
PremiumCompany Announcements
Fusion Antibodies Announces Change in Director Shareholding
PremiumCompany Announcements
Fusion Antibodies Announces Share Capital Structure
PremiumCompany Announcements
Fusion Antibodies Receives U.S. Patent Allowance for OptiMAL® Platform
PremiumCompany Announcements
Fusion Antibodies to Host Investor Presentation on Recent Trading Update
PremiumCompany Announcements
Fusion Antibodies Issues Shares to Non-Executive Directors
PremiumCompany Announcements
Fusion Antibodies Announces Shareholder Name ChangePremiumCompany Announcements
Fusion Antibodies Achieves 71% Revenue Growth Amid Strategic DiversificationOptions Prices
Currently, No data available
---
Ownership Overview
5.73% Insiders
―
Mutual Funds
― Other Institutional Investors
94.27% Public Companies and
Individual Investors
FAB FAQ
What was Fusion Antibodies Plc’s price range in the past 12 months?
Fusion Antibodies Plc lowest share price was 2.80p and its highest was 12.00p in the past 12 months.
What is Fusion Antibodies Plc’s market cap?
Fusion Antibodies Plc’s market cap is £8.13M.
When is Fusion Antibodies Plc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Fusion Antibodies Plc’s earnings last quarter?
Currently, no data Available
Is Fusion Antibodies Plc overvalued?
According to Wall Street analysts Fusion Antibodies Plc’s price is currently Overvalued.
Does Fusion Antibodies Plc pay dividends?
Fusion Antibodies Plc does not currently pay dividends.
What is Fusion Antibodies Plc’s EPS estimate?
Fusion Antibodies Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusion Antibodies Plc have?
Fusion Antibodies Plc has 113,656,250 shares outstanding.
What happened to Fusion Antibodies Plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Fusion Antibodies Plc?
Currently, no hedge funds are holding shares in GB:FAB
Company Description
Fusion Antibodies Plc
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Technical Analysis
IXICO plc
―
Oxford BioDynamics
―
HemoGenyx Pharmaceuticals Plc
―
ValiRx plc
―
Aptamer Group Plc
―